Excretion of linagliptin, CD1790, and total radioactivity in urine and feces (both up to 120 h) after intravenous administration of 5 mg of [14C]linagliptin and oral administration of 10 mg of [14C]linagliptin
Results are presented as geometric means (gMeans).
| Parameter | Route of Administration | Linagliptin (Urine) | CD1790 (Urine) | Total Radioactivity (Urine) | Total Radioactivity (Feces) | ||||
|---|---|---|---|---|---|---|---|---|---|
| gMean | CV | gMean | CV | gMean | CV | gMean | CV | ||
| % | % | % | % | ||||||
| Fe0–24 (%) | i.v. | 18.0 | 9.76 | 0.06 | 39.0 | 24.9 | 7.74 | 0.311 | 8310 |
| Fe0–48 (%) | 19.9 | 9.44 | —* | —* | 27.8 | 7.15 | 7.53 | 2930 | |
| Fe0–120 (%) | 21.2 | 9.57 | —* | —* | 29.7 | 6.91 | 41.7 | 39.7 | |
| Fe0-tz (%) | 21.2 | 9.57 | 0.07 | 44.4 | 30.8 | 6.74 | 58.2 | 4.81 | |
| Fe0–24 (%) | Oral | 1.3 | 299 | 0.04 | 38.8 | 3.4 | 127 | 0.132 | 524000 |
| Fe0–48 (%) | 1.9 | 244 | —* | —* | 4.3 | 120 | 55.5 | 63.0 | |
| Fe0–120 (%) | 2.4 | 1.69 | —* | —* | 5.1 | 107 | 82.3 | 6.32 | |
| Fe0-tz (%) | 2.4 | 1.69 | 0.04 | 47.8 | 5.4 | 100 | 84.7 | 5.80 | |
↵* Not calculated as no data beyond 24 h.